| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $517,950 ) |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R03CA286669 | Divergent Functions of ERK2 Substrate Binding Domains in Pathogenesis of KRAS-Driven Pancreatic Cancer | 000 | 2 | NIH | 11/14/2024 | $94,000 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R13AI188924 | ThymUS 2025 International Conference on Lymphopoiesis | 000 | 1 | NIH | 11/15/2024 | $3,200 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM144131 | Deciphering Networks Controlling DNA Amplification | 001 | 4 | NIH | 11/5/2024 | $420,750 |
| | 2025 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM122517 | Structural Bioinformatics of Proteins and Protein Complexes and Applications to Cancer Biology | 000 | 7 | NIH | 11/6/2024 | $0 |
| | 2025 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM144131 | Deciphering Networks Controlling DNA Amplification | 000 | 3 | NIH | 11/5/2024 | $0 |
| | 2025 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM119560 | Molecular Mechanisms Underlying Adaptor-Mediated Integrin Signaling in a Species-Specific Manner | 000 | 8 | NIH | 11/6/2024 | $0 |
| | 2025 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM150538 | Telomerase RNP Prisonbreaks from Phase-Separated Nuclear Body | 000 | 2 | NIH | 10/24/2024 | $0 |
| | 2025 | 2023 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R03CA273479 | Pancreatic adenocarcinoma secretome as a dynamic biomarker for patient stromal reprogramming efficacy | 000 | 2 | NIH | 11/5/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $22,161,096 ) (Continued on the next page) |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA214799 | Compensatory Mechanisms that Promote Homologous Recombination in BRCA1 Mutant Cancers | 000 | 6 | NIH | 8/8/2024 | $470,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00CA267678 | Positive Activities for Asian American Cancer Patients and Caregivers | 000 | 3 | NIH | 4/12/2024 | $249,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00CA267678 | Positive Activities for Asian American Cancer Patients and Caregivers | 001 | 3 | NIH | 8/9/2024 | $26,194 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA245871 | MTAP, 5'-deoxy-5'-methylthioadenosine, and the dysregulation of symmetric dimethylarginine in cancer | 000 | 5 | NIH | 5/13/2024 | $406,375 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM122517 | Structural Bioinformatics of Proteins and Protein Complexes and Applications to Cancer Biology | 001 | 7 | NIH | 3/12/2024 | $670,032 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM122517 | Structural Bioinformatics of Proteins and Protein Complexes and Applications to Cancer Biology | 002 | 7 | NIH | 6/19/2024 | $74,448 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA259188 | Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy | 000 | 4 | NIH | 4/5/2024 | $383,481 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA286231 | A novel engineered IL-21-based immunocytokine as a therapeutic approach for tumor targeting in renal cancer | 000 | 1 | NIH | 6/4/2024 | $483,395 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UG3HL170034 | Asian American Community Cohort and Equity Study (ACCESS) | 001 | 2 | NIH | 7/25/2024 | $344,654 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UG3HL170034 | Asian American Community Cohort and Equity Study (ACCESS) | 001 | 2 | NIH | 7/25/2024 | $71,111 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UG3HL170034 | Asian American Community Cohort and Equity Study (ACCESS) | 001 | 2 | NIH | 7/25/2024 | $71,111 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UG3HL170034 | Asian American Community Cohort and Equity Study (ACCESS) | 001 | 2 | NIH | 7/25/2024 | $71,111 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UG3HL170034 | Asian American Community Cohort and Equity Study (ACCESS) | 001 | 2 | NIH | 7/25/2024 | $71,111 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA277402 | A Phase I Proof-of-Concept Study of CBL0137 Combined with Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma | 000 | 2 | NIH | 6/3/2024 | $208,738 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD017675 | Reducing Urban Cervical Cancer Disparities Using a Tailored mHealth Intervention to Enhance Colposcopy Attendance | 002 | 2 | NIH | 6/4/2024 | $49,251 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01GM141513 | Designing selective kinase inhibitors via deep learning | 001 | 3 | NIH | 6/18/2024 | $54,956 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01GM141513 | Designing selective kinase inhibitors via deep learning | 002 | 3 | NIH | 7/9/2024 | $0 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01GM141513 | Designing selective kinase inhibitors via deep learning | 000 | 3 | NIH | 11/9/2023 | $494,601 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD017675 | Reducing Urban Cervical Cancer Disparities Using a Tailored mHealth Intervention to Enhance Colposcopy Attendance | 001 | 2 | NIH | 12/7/2023 | $633,245 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UH3CA271230 | Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer | 000 | 3 | NIH | 7/24/2024 | $400,915 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA262551 | Folic Acid Supplementation and Colitis-associated Colon Carcinogenesis | 000 | 3 | NIH | 4/11/2024 | $525,677 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA282851 | Estrogen Suppression as a Strategy to Enhance Immunotherapy Efficacy in EGFR-Mutated Non-Small Cell Lung Cancer | 000 | 1 | NIH | 5/23/2024 | $483,395 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD018511 | Neighborhood, social connectedness, and allostatic load in US Chinese immigrants | 001 | 2 | NIH | 5/25/2024 | $46,877 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | U54CA272686 | Novel small molecule agents to correct pathogenic VHL missense mutations | 002 | 3 | NIH | 8/22/2024 | $200,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA283396 | Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms | 000 | 2 | NIH | 6/20/2024 | $671,691 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | U54CA272686 | Novel small molecule agents to correct pathogenic VHL missense mutations | 001 | 3 | NIH | 8/12/2024 | $1,170,059 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R03CA286669 | Divergent Functions of ERK2 Substrate Binding Domains in Pathogenesis of KRAS-Driven Pancreatic Cancer | 000 | 1 | NIH | 12/13/2023 | $94,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD018511 | Neighborhood, social connectedness, and allostatic load in US Chinese immigrants | 000 | 2 | NIH | 12/9/2023 | $602,694 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R25CA259244 | Empowering the Next Generation of Cancer Professionals: the Fox Chase Cancer Center-University of Delaware Partnership for Undergraduate Research and Career Development | 001 | 3 | NIH | 4/18/2024 | $15,175 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R37AI110985 | Regulation of hematopoiesis by ribosomal protein paralogs | 001 | 10 | NIH | 5/23/2024 | $56,100 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R25CA259244 | Empowering the Next Generation of Cancer Professionals: the Fox Chase Cancer Center-University of Delaware Partnership for Undergraduate Research and Career Development | 000 | 3 | NIH | 2/19/2024 | $64,519 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R37AI110985 | Regulation of hematopoiesis by ribosomal protein paralogs | 000 | 10 | NIH | 1/23/2024 | $504,900 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | U01CA260369 | Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients | 000 | 4 | NIH | 7/31/2024 | $337,277 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM155098 | Interplay between DNA base excision repair and transcriptional regulation | 000 | 1 | NIH | 9/13/2024 | $470,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA282766 | Interrogating MRCK Protein Kinases in Ovarian Cancer | 001 | 1 | NIH | 8/29/2024 | $235,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM150538 | Telomerase RNP Prisonbreaks from Phase-Separated Nuclear Body | 001 | 2 | NIH | 8/6/2024 | $239,252 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM119560 | Molecular Mechanisms Underlying Adaptor-Mediated Integrin Signaling in a Species-Specific Manner | 001 | 8 | NIH | 6/26/2024 | $48,152 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD018146 | Examining the Relationship between Residential History at Midlife and Prostate Cancer Outcomes | 001 | 2 | NIH | 6/13/2024 | $36,601 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM144131 | Deciphering Networks Controlling DNA Amplification | 001 | 3 | NIH | 6/28/2024 | $46,750 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R37CA283552 | Targeting DHX9 to trigger viral mimicry and immunotherapy responsiveness in Small Cell Lung Cancer (SCLC) | 000 | 1 | NIH | 7/31/2024 | $649,679 |
|
